ArticleCureus2025
Fatal Toxic Megacolon Following Nivolumab and Ipilimumab Therapy in Metastatic Melanoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this case report, we describe a 76-year-old man with advanced malignant melanoma who developed severe colitis and toxic megacolon following nivolumab plus ipilimumab therapy. Despite treatment with prednisolone, infliximab, and vedolizumab, the patient's condition deteriorated, resulting in hypoalbuminemia and unfeasibility of surgical intervention. Elevated C-reactive protein (CRP) levels served as a critical diagnostic clue, prompting abdominal radiography, which subsequently confirmed the diagnosis of toxic megacolon. This case highlights a rare but life-threatening complication of immune checkpoint inhibitors and underscores the challenges in managing refractory immune-related colitis. Given the increasing use of immune checkpoint inhibitors in clinical practice, this report will be of significant interest to readers by emphasizing the importance of timely recognition, CRP monitoring, and intervention to prevent fatal outcomes in similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.